
Microbiotica's MB097 shows safety and promising efficacy in advanced melanoma Phase 1b trial with KEYTRUDA.
Microbiotica presented positive Phase 1b trial results for MB097, a precision microbiome therapy combined with KEYTRUDA, in advanced melanoma patients resistant to anti-PD-1 therapy. The trial showed MB097 was safe, well tolerated, and led to signifi...





